Brokerages Set Genmab A/S Sponsored ADR (NASDAQ:GMAB) Target Price at $39.25

Genmab A/S Sponsored ADR (NASDAQ:GMAB) has been assigned an average recommendation of “Moderate Buy” from the eleven brokerages that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $40.00.

A number of analysts have recently weighed in on the stock. HC Wainwright upped their price target on shares of Genmab A/S from $35.00 to $36.00 and gave the stock a “buy” rating in a report on Friday, August 15th. Guggenheim upgraded shares of Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price objective for the company in a research report on Tuesday. Zacks Research downgraded Genmab A/S from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 19th. Truist Financial lifted their price target on Genmab A/S from $45.00 to $46.00 and gave the company a “buy” rating in a research note on Tuesday, July 8th. Finally, Wall Street Zen upgraded Genmab A/S from a “hold” rating to a “buy” rating in a research report on Monday, July 28th.

Institutional Trading of Genmab A/S

Several hedge funds and other institutional investors have recently made changes to their positions in GMAB. Squarepoint Ops LLC grew its stake in shares of Genmab A/S by 1,235.0% in the fourth quarter. Squarepoint Ops LLC now owns 117,507 shares of the company’s stock worth $2,452,000 after purchasing an additional 108,705 shares during the last quarter. Vise Technologies Inc. lifted its holdings in Genmab A/S by 41.7% during the 4th quarter. Vise Technologies Inc. now owns 12,892 shares of the company’s stock worth $269,000 after buying an additional 3,794 shares during the period. GTS Securities LLC bought a new stake in shares of Genmab A/S in the 4th quarter valued at about $1,552,000. Mackenzie Financial Corp bought a new stake in shares of Genmab A/S in the 4th quarter valued at about $689,000. Finally, Employees Retirement System of Texas acquired a new stake in shares of Genmab A/S in the fourth quarter valued at about $1,648,000. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Stock Performance

NASDAQ:GMAB opened at $28.84 on Friday. The company has a market cap of $18.50 billion, a price-to-earnings ratio of 14.49, a PEG ratio of 1.72 and a beta of 0.93. Genmab A/S has a fifty-two week low of $17.24 and a fifty-two week high of $29.51. The stock has a fifty day moving average price of $24.82 and a 200-day moving average price of $21.98.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.54 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.15. The business had revenue of $925.00 million during the quarter, compared to the consensus estimate of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. Genmab A/S has set its FY 2025 guidance at EPS. Research analysts predict that Genmab A/S will post 1.45 EPS for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.